Gujarat Terce Laboratories Ltd524314Corporate

Pharmaceuticals Latest results: Sep 2021 10 quarters of data

₹40.50

MCap ₹29 Cr

Gujarat Terce Laboratories Ltd — Stock analysis & AI research Gujarat Terce Laboratories Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹10 Cr

Sales · Sep 2021

+40.7% YoY

₹1 Cr

Operating Profit · Sep 2021

+381.8% YoY

5.2%

OPM % · Sep 2021

+246.7% YoY

₹0 Cr

Net Profit · Sep 2021

+2350.0% YoY

₹0.61

EPS · Sep 2021

+2133.3% YoY

📝 Gujarat Terce Laboratories Ltd — results explained

Quarter ended September 2021 (Q2 FY22)

Gujarat Terce Laboratories Ltd reported revenue of ₹10 crore for the quarter ended September 2021 (Q2 FY22), up 40.7% from ₹7 crore in the same quarter last year, and up 1.9% sequentially over the June 2021 quarter.

The company swung to a net profit of ₹0 crore from a net loss of ₹0 crore a year earlier. Earnings per share (EPS) came in at ₹0.61.

Operating profit stood at ₹1 crore — an operating margin (OPM) of 5.2%, compared with 1.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY20, Gujarat Terce Laboratories Ltd posted revenue of ₹38 crore, with a net profit of ₹0 crore.

Valuation snapshot

At the current price of ₹40.50, 524314 has a market capitalisation of ₹29 crore.

Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 40.03%, public shareholders 59.98% of Gujarat Terce Laboratories Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹29 Cr

Current Price ?

₹40.5

P/E ?

N/A

Industry P/E ?

22.40

P/B ?

2.94

P/S ?

N/A

P/FCF ?

16.91

Enterprise Value ?

₹30 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

39.8%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹10 Cr

PAT — latest qtr ?

₹0 Cr

YoY qtr sales growth ?

40.7%

YoY qtr profit growth ?

2,350.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹1 Cr

Debt to Equity ?

0.13

Interest Coverage ?

1.6

Current Ratio ?

N/A

Ownership

Promoter holding ?

40.03%

Change in promoter holding ?

3.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

11.5%

Return 6 months ?

1.3%

🗓️ Quarterly results (10 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Jun 2021	Sep 2021	YoY %	QoQ %
Sales	8	8	7	11	10	9	5	7	10	10	+40.7%	+1.9%
Operating Profit	1	0	-1	2	0	-0	-0	0	2	1	+381.8%	-67.5%
Other Income	0	0	0	0	0	0	0	0	0	0	-11.1%	+14.3%
Interest	0	0	0	0	0	0	0	0	0	0	-41.2%	+100.0%
Depreciation	0	0	0	0	0	0	0	0	0	0	+25.0%	+0.0%
Profit Before Tax	1	0	-1	2	0	-0	-0	-0	2	0	+4700.0%	-71.2%
Net Profit	1	0	-1	2	0	-1	-0	-0	2	0	+2350.0%	-71.9%
EPS	0.77	0.49	-1.64	2.28	0.50	-0.77	-0.59	-0.03	2.16	0.61	+2133.3%	-71.8%
OPM %	8.1%	1.7%	-16.0%	16.5%	4.5%	-5.4%	-8.0%	1.5%	16.4%	5.2%	+246.7%	-68.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	Prev FY	FY20	TTM	YoY %
Sales	—	₹38 Cr	—	—
Operating Profit	—	₹1 Cr	—	—
OPM %	—	1.84%	—	—
NPM %	—	0.72%	—	—
Other Income	—	₹0 Cr	—	—
Depreciation	—	₹0 Cr	—	—
Interest	—	₹0 Cr	—	—
EBIT	—	₹0 Cr	—	—
PBT	—	₹0 Cr	—	—
Tax	—	—	—	—
Net Profit	—	₹0 Cr	—	—
EPS	—	₹0.37	—	—
Material Cost	—	—	—	—
Employee Cost	—	—	—	—
Extraordinary Items	—	—	—	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	7.42	7.42	7.42	7.79	+5.0%
Reserves	-0.56	-0.31	-0.94	1.94	+306.4%
Borrowings	7.27	3.87	0.94	1.30	+38.3%
Other Liabilities	14.39	12.29	15.41	13.52	-12.3%
Total Liabilities	28.52	23.27	22.83	24.55	+7.5%
Fixed Assets	3.99	3.69	3.65	3.25	-11.0%
CWIP	0.00	0.00	0.00	0.00	—
Investments	0.27	0.27	0.52	1.35	+159.6%
Other Assets	24.26	19.31	18.66	19.95	+6.9%
Total Assets	28.52	23.27	22.83	24.55	+7.5%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	0.03	2.60	3.06	1.71	-44.1%
Cash from Investing Activity	0.62	-0.46	0.46	-0.11	-123.9%
Cash from Financing Activity	-0.12	-4.08	-2.83	0.47	+116.6%
Net Cash Flow	0.52	-1.94	0.69	2.08	+201.4%
Free Cash Flow	-0.03	2.53	3.41	1.69	-50.4%
CFO/OP	-3%	205%	81%	46%	-43.2%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	62.34	43.11	36.86	37.45	+1.6%
Inventory Days	83.56	81.09	71.03	79.48	+11.9%
Days Payable	110.35	97.39	69.87	33.67	-51.8%
Cash Conversion Cycle	35.56	26.81	38.02	83.26	+119.0%
Working Capital Days	-20.21	-7.69	-13.89	4.61	+133.2%
ROCE %	-14.80%	9.72%	41.41%	39.78%	-3.9%

👥 Shareholding (latest 4 periods)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	37.03%	40.03%	40.03%	40.03%	+0.0%
Public	62.97%	59.98%	59.97%	59.98%	+0.0%
No. of Shareholders	13,812	13,805	13,750	13,755	+0.0%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	524314 Gujarat Terce	₹47.03	29	17.0	46	2	7.2%	4.6%	-5.4%	326.5%	-17.0%	-345.2%

❓ Frequently asked questions

What was Gujarat Terce Laboratories Ltd's revenue in Q2 FY22?

What was Gujarat Terce Laboratories Ltd's net profit in Q2 FY22?